[Immunohistochemical study and biodistribution of monoclonal antibody (Nd2) against human pancreatic cancer].
Nd2 was a murine monoclonal antibody produced against a mucin fraction purified from xenografts of the human pancreatic cancer cell line SW1990. The reactivity of Nd2 was reduced by trypsin, but was not influenced by neuraminidase, so the epitope recognized by Nd2 may involve peptide but not sialic acid. The antigen recognized by Nd2 was present in 83% of pancreatic cancer, whereas in tissue of normal pancreas and chronic pancreatitis no reactivity was detected. By biodistribution study, tumor/blood ratio was elevated 8.27 on the 7th day after injection of 125I-labeled Nd2, while tissue/blood ratio in liver was remained 0.53. These results indicate that Nd2 had possibilities in clinical application such as radio-immunodetection and targeting therapy of pancreatic cancer.